AcuityMD drew significant attention this week after disclosing an $80 million Series C round that values the MedTech commercialization software provider at about $955 million. The funding, led by StepStone Group with participation from Benchmark, Redpoint, ICONIQ, and Atreides Management, lifts total capital raised to more than $160 million.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company reports that nearly 500 MedTech firms, including 16 of the top 20, now use its platform to navigate a fragmented market. This level of adoption underscores AcuityMD’s role in providing data-driven tools for commercial teams and could underpin recurring revenue growth as customers embed the software into daily workflows.
New capital will be directed toward three priorities: advancing “agentic AI” tools for commercial teams, deepening the firm’s data ontology, and expanding beyond sales-focused use cases to cover the broader MedTech product lifecycle. Management highlights integration of claims data, FDA filings, and government records as a way to create defensible data assets and higher switching costs.
Separately, AcuityMD spotlighted real-world use of its AcuityAI product at Kuros Biosciences, where a sales leader reportedly generated an AI-driven business plan for a new national health system contract. The workflow compressed hours of research into a single on-demand output, suggesting meaningful productivity gains and strengthening evidence of product-market fit in medtech sales operations.
The company also emphasized the rapid shift of procedures into ambulatory surgery centers, particularly in orthopedics and cardiovascular care, and engaged with customers at the ASCA 2026 conference. By tailoring its analytics to ambulatory surgery center growth and site-of-care strategy, AcuityMD aims to align its platform with one of the fastest-growing segments in healthcare delivery.
Taken together, the fresh capital, expanding customer base, and demonstrated AI use cases position AcuityMD to invest aggressively in product breadth and data depth. While execution on AI and lifecycle expansion remains critical, this week’s developments point to a company consolidating its role as a key infrastructure provider in MedTech commercialization and analytics.